GLP-1 Coverage and Cost Management: A Guide for Plan Sponsors
.jpg)
.webp)
Few decisions put more pressure on a benefits strategy than whether, and how, to cover GLP-1 drugs.
GLP-1s can deliver meaningful clinical benefits for people living with diabetes and obesity1,2, but the expanding list of emerging indications for these drugs can add to plan sponsors' pharmacy spending. Coverage of GLP-1s for weight management has pushed the issue even further, forcing organizations to consider what they can support today and what that commitment could look like over time.
This guide outlines the clinical considerations, coverage decisions, and cost management strategies that can help benefits leaders build a GLP-1 strategy that works for both their populations and fits their budgets.
What Are GLP-1s and How Do They Work?
GLP-1 stands for glucagon-like peptide-1; a hormone the body naturally produces to help regulate blood sugar and appetite. GLP-1 medications mimic the hormone’s effects, prompting the body to release insulin when blood sugar rises, slow digestion, and signal the mind to reduce hunger. Together, those effects can improve blood sugar control and contribute to significant weight loss 1,2.
In recent years, the GLP-1 drug class has grown. Tirzepatide, marketed as Mounjaro and Zepbound, targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), another hormone involved in blood sugar and appetite regulation, with newer therapies in development that target additional metabolic pathways, giving the class plenty of room to evolve.
The evolution of the class and its expanding indications are a big reason GLP-1s have become such a significant benefits challenge, as GLP-1s originally developed to treat type 2 diabetes are now being used for weight management, and more recently, indications such as cardiovascular risk reduction and obstructive sleep apnea.
For coverage purposes, “GLP-1” is a broad label, but the specific product and the condition being treated can influence what a plan covers and how that coverage is managed.
Which GLP-1s Are Approved for Weight Loss?
GLP-1 coverage gets more complicated when the same active ingredient can show up with different brand names and indications. Semaglutide is a good example: Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management, certain types of liver disease, and cardiovascular risk reduction. Tirzepatide follows a similar path: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management.
When it comes to weight management, clinical guidelines generally support treatment for individuals living with obesity or who are considered overweight with a weight-related health condition; FDA labeling also calls for treatment alongside dietary changes and physical activity.
Here’s how the major products differ:
*FDA-approved uses indicated on the table are as of October 2026.
The overlap creates a practical coverage question for a pharmacy benefit: what should GLP-1 coverage look like when the same active ingredient can be prescribed for different conditions? A plan may cover semaglutide for type 2 diabetes while taking a different approach for weight management. The same goes for tirzepatide. Without a way to distinguish indication, utilization rules can miss an important part of the coverage decision. Knowing which product is being prescribed and why gives a plan a clearer starting point for deciding how coverage should work.
Why Has GLP-1 Coverage Become Such a Big Benefits Issue?
GLP-1s have become a growing share of pharmacy spending which is forcing plan sponsors to think more carefully about how coverage decisions affect the broader benefit. According to The American Academy of Actuaries, in early 2025, a small group of GLP-1 medications accounted for approximately 21% of total prescription costs for large pharmacy coalitions, up from just 1% in 2020. With the rise in GLP-1 spending, coverage design a high priority for benefits teams, and how a plan defines eligibility and manages utilization can shape both pharmacy spending and what happens beyond the pharmacy benefit.
Coverage decisions increasingly have to account for:
- Utilization: GLP-1 use continues to expand, putting more pressure on pharmacy spending.
- Continuation of treatment: 53.6% of patients discontinued GLP-1 treatment within one year, according to a 2025 study, making long-term spending harder to predict.
- Coverage strategy: Eligibility and utilization requirements can influence both access and overall spending.
- Indication: The same active ingredient can be used for different conditions, which can affect how a plan structures coverage and utilization management.
- Long-term impact: Pharmacy costs appear immediately, while potential changes in medical spending may take longer to show up.
How Much Do GLP-1s Cost Employers?
The cost of GLP-1s for employers depends on how a plan covers and manages these medications. According to WTW, in the first quarter of 2025, spending on selected GLP-1 medications reached $27.24 per member per month (PMPM), or about $327 per member annually, after discounts and rebates, up from $4.34 PMPM in 2022.
For an employer, even a relatively small increase in per-member spending can add up quickly as GLP-1 use grows. The challenge is deciding how much of that spend the plan should take on and where coverage rules can help manage it without creating unnecessary barrier for members who need treatment, making the design of the benefit just as important as the price of the medications themselves.
What Does GLP-1 Coverage Look Like Today?
GLP-1 coverage has moved well beyond a simple yes-or-no decision. Some plans cover medications for weight management, others limit coverage to certain indications, and some exclude coverage for weight loss altogether. Government programs add another layer, with rules that vary by program and indication.
Commercial plans generally have more flexibility in setting their own policies. Medicare operates within federal requirements, while Medicaid coverage can vary by state. A member’s access can look very different depending on the benefit behind the prescription.
How Does Medicare Cover GLP-1s?
Medicare Part D can cover GLP-1s for approved medical conditions such as type 2 diabetes and cardiovascular risk reduction. The cardiovascular indication is particularly relevant because Wegovy is approved to reduce the risk of major cardiovascular events in certain adults who are overweight or obese and have established cardiovascular disease.
Weight-management coverage follows a different path. Beginning July 1, 2026, eligible Medicare beneficiaries can access certain GLP-1s, including Wegovy, through the Medicare GLP-1 Bridge program. The program, which is currently extended through December 31, 2027, sits outside the standard Part D benefit and comes with its own eligibility and prior authorization requirements.
How Should Plans Manage GLP-1 Utilization?
Coverage sets the boundaries, but Utilization Management (UM) determines what happens inside them. A GLP-1 may be prescribed for different indications, at different stages of treatment, and under very different clinical circumstances. Each can affect how a plan manages cost, access, and ongoing treatment.
Several areas deserve particular attention:
- Clinical criteria
If weight management is covered, eligibility requirements should be clear. Criteria may consider BMI, weight-related conditions, prior treatment and physician documentation, while allowing for appropriate clinical exceptions. - Treatment progression
Step therapy can direct utilization toward lower-cost options when clinically appropriate, but criteria should account for patients who may need a GLP-1 earlier in treatment. The right approach can vary by indication and individual circumstances. - Medication supply
GLP-1 dosing can change during initiation and titration, making a 90-day supply impractical when treatment is adjusted or discontinued. Shorter supplies during treatment initiation can reduce exposure to unused medication reducing unnecessary spend. - Technology and visibility
Technology can make UM more targeted by helping plans identify members who may benefit from clinical support, surface utilization patterns, and connect coverage decisions with what’s happening after a prescription is approved - Clinical Programs
Clinical programs can be leveraged to ensure clinically-appropriate prescribing of GLP-1s and to reduce potential for unnecessary use of multiple GLP-1 medications through interventions like retrospective drug utilization review, point-of-sale safety alerts, and high-touch programs.
UM works best when the rules reflect how GLP-1 therapy is regularly being prescribed and used, which means looking beyond whether a claim was paid and asking what’s happening across the benefit.
Why Should GLP-1 Coverage Include Clinical Support?
GLP-1 treatment can involve decisions well beyond the initial prescription. Clinical support can help members navigate behavior change, treatment response, and ongoing care whole giving plans more visibility into what happens after therapy begins.
We really need to be thinking about this as a chronic disease management program, not just a drug benefit.
- Sara Izadi, PharmD, Chief Clinical Officer
What Does Integrated GLP-1 Support Look Like?
A clinical program that’s integrated alongside a UM strategy can offer members more support than medication prescribing alone while providing plan sponsors with more visibility into what happens after a prescription is issued.
The Rx Activate program, developed by Judi Rx™ in partnership with Vida Health, combines medication management with behavioral intervention, nutrition guidance, and coordination with primary care. The model can support several points in the treatment journey:
- Before treatment: Help determine whether medication therapy is appropriate and identify members who may benefit from non-pharmacologic support.
- During treatment: Monitor treatment response, reinforce healthy behaviors and help address barrier to adherence.
- When treatment changes: Support dose adjustments, identify when therapy may no longer be appropriate and help members maintain progress if medication is discontinued.
Data from Rx Activate offers a closer look at how clinical support can influence treatment patterns. from whether members initiate GLP-1 therapy to how consistently they remain on treatment. Among members already taking a weight-loss GLP-1 at baseline, 29% discontinued treatment during the program enrollment period. Only 20% of treatment-native members started a GLP-1, compared to a modeled estimate of 65%, while medication adherence improved with 15% more members achieving Proportion of Days Covered (PDC) of ≥80% after enrollment. The analysis estimated $1.45 million in annualized gross pharmacy savings.
These findings highlight the value of integrating clinical support with traditional UM to better understand treatment initiation, continuation, and adherence, as well as how those patterns may impact overall pharmacy spending.
What Does Obesity Cost Without Treatment?
A 2026 study of more than 700,000 privately insured U.S. adults found that individuals living with obesity had approximately $1,776 more in annual medical expenditures than those with a healthy weight, with higher spending across inpatient, outpatient, and pharmacy care.
GLP-1s could change some of these costs by improving weight and cardiometabolic health. Clinical trials have shown meaningful improvements in weight loss with GLP-1 treatment, along with improvements in several cardiometabolic measures. Semaglutide, for example, reduced the risk of major cardiovascular events by 20% in a large clinical trial of adults who were overweight or obese and established cardiovascular disease.
For plans, understanding the financial implications requires looking beyond the immediate cost of medication. Pharmacy spending begins when treatment starts, while any changes in medical utilization may take longer to emerge and depend on treatment response and how long members remain on therapy.
What is Prior Authorization for GLP-1 Medications?
Prior authorization (PA) gives plans a way to confirm that a prescription aligns with the member’s diagnosis, an FDA-approved indication, and the plan’s clinical criteria before a claim is paid.
For GLP-1 coverage, consistency is critical; PA criteria should apply across all indications, including GLP-1 prescriptions for type 2 diabetes, rather than focusing solely on products for weight management. When the same active ingredients appear across different indications, criteria addressing only weight management prescriptions can leave gaps in a plan sponsor’s PA strategy.
What Should Benefits Leaders Ask About GLP-1 Prior Authorization?
A PA strategy can tell benefits leaders much more than just how many prescription claims were approved. Asking the right questions can reveal whether coverage criteria is working as intended and where utilization is moving across the benefit.
When reviewing a GLP-1 PA strategy, consider asking:
- What percentage of GLP-1 PA requests are approved?
- What are the most common reasons PA requests are being denied?
- Which products are approved most frequently?
- How do PA approval rates differ by indication?
- What happens after a PA denial?
- Could changes to UM strategies or coverage criteria affect rebates?
Members who obtain GLP-1 medications outside their pharmacy benefit may not appear in pharmacy claims or PA data. Plan sponsors should account for this gap when evaluating GLP-1 utilization and coverage decisions. Reviewing available pharmacy data alongside other relevant sources can help provide a more complete view of utilization, although prescriptions obtained outside the benefit may remain difficult to measure.
How Can Plan Sponsors Build a GLP-1 Strategy?
Building a GLP-1 strategy means deciding how the benefit should work today while also establishing a framework for adjusting it as utilization and treatment options evolve. A broader pharmacy strategy can help put benefit design decisions into context with respect to coverage, clinical criteria, UM, and financial modeling all playing a role. However, all of these decisions need to work together rather than operate independent of one another.
A practical GLP-1 strategy requires plan sponsors to do five things:
- Define the Coverage Approach
Start by deciding which indications the benefit will cover and where coverage should differ. Weight-management coverage can require a different approach than coverage for type 2 diabetes or another approved indication, particularly when clinical criteria and utilization patterns vary across indications. - Set Clinical Criteria
Clinical requirements should give the plan a consistent basis for approving GLP-1 therapies without creating unnecessary barriers to appropriate care. Criteria may address clinical factors like BMI and weight -related health conditions as well as other requirements such as requiring documentation while allowing clinically appropriate exceptions where warranted. - Align Utilization Management
UM should complement coverage criteria rather than operate separately from it. A PA strategy can verify that prescription claims meet the plan's clinical requirements, while step therapy can direct members toward lower-cost treatment where clinically appropriate. The important part is making sure these controls work together instead of creating gaps between coverage rules and what happens at the pharmacy. - Model the Financial Impact
A coverage change can impact plan spending in ways that are easy to miss when pharmacy claims are the only consideration. Before altering a plan benefit design, model any anticipated changes on net pharmacy cost, then consider how the decision could affect rebates and medical spending. - Revisit the Strategy
GLP-1 coverage strategy should not be treated as a permanent, one-time decision. Utilization can change as prescribing patterns develop, new indications get approved, and as new therapies and formulations become available to members and clinicians. A regular review gives plan sponsors an opportunity to adjust their coverage or UM strategies if they are no longer producing the intended results.
How Do GLP-1 Rebates Affect Total Cost?
Rebates can influence the financial impact of a GLP-1 coverage decision. A UM restriction, such as step therapy or a days supply limit, may reduce overall pharmacy spending while also changing which GLP-1 prescriptions qualify for manufacturer rebates.
Before changing UM rules, plan sponsors should model any potential impact on:
- Pharmacy spend
- Rebate revenue
- Member costs
- Potential medical costs
- Access and utilization
Because these factors can shift together, lower pharmacy claims don't always translate into lower overall costs. For example, a UM restriction that reduces the number of paid claims could also reduce rebate revenue tied to eligible prescriptions. Modeling these trade-offs before making a coverage change helps plan sponsors understand the potential financial impact before a new policy becomes part of the benefit design. Rather than assuming a restriction will lower costs, they can use an impact analysis to assess what the plan stands to gain or give up.
GLP-1 Coverage Is a Moving Target
GLP-1 coverage will keep evolving as new therapies enter the market, new indications are approved, and as utilization changes. Plan sponsors need a pharmacy strategy that can evolve with them. Judi Rx gives plan sponsors greater control over their pharmacy benefit, with the transparency and tools to make smarter decisions about spend and coverage, especially GLP-1s.
Get in touch with our team to learn how Judi Rx can help you build benefits programs that work for you and your plan members.
References:
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
.webp)
